Heart failure as a consequence of myocardial fibrosis is the world’s biggest killer and represents a significant unmet medical need. No therapies currently exist that either directly target the heart or the fibrotic process itself. We have discovered a heart specific regulator of fibrosis – the long noncoding RNA, Wisper. By using our first-in-class proprietary approach to target Wisper, we are able to block myocardial fibrosis and treat heart failure in pre-clinical animal models.

We are developing a first-in-class biopharmaceutical therapy to treat heart failure.

Why is the GNUbiotics ingredient unique?

• The most diverse HMO mimic product available. The more diverse the more proven efficiency.
• Ingredient produced with no GMO or enzymatic processes. 100% Natural source.
• Proven efficacy for microbiome modulation.

In response to the rising demand for healthier foods we are developing functional and structural mimics of Human Milk Oligosaccharides, (HMOs) for the consumer health market. Our products reproduce the natural diversity and complexity of HMOs and have been shown to be beneficial in preventing the onset of gut infection and protect against the effect of antibiotic use.

Leveraging on its key technological competences, polymers chemistry, cell biology and materials sciences, Volumina Medical has developed a technology platform applicable to different areas of reconstructive, plastic and aesthetic surgery, a fast-growing market (+11% annual growth since 2013, expected to be 12% in during the next five years).

The company is committed to become a leading and reliable actor in the field of regenerative technologies of soft tissues, providing safe cutting-edge technologies, limiting uncertainty and saving time both for patients and surgeons. The company strives to grow through its strategy: Understand, Execute, Optimize, Accelerate.

Volumina Medical’s mission is to develop its first product, an injectable scaffold, and to obtain the approval to penetrate the European Market first with an indication for intermediate volumes.

We are SEED Biosciences, a spinoff from the Swiss Federal Institute of Technology (EPFL). We make DispenCell. One click, one cell.

We are a bioengineering company – We offer cutting edge laboratory technologies that bring personalized organ and disease models to scientists and medical doctors.

SUN bioscience was founded in 2016. It’s core technologies stem from research conducted at the Swiss Federal Institute of Technology (EPFL), ranked Europe’s fourth most innovative university. SUN bioscience is connected to a large network of stem cell scientists across Europe and the North American continent.